GSK plc Announces Updated Data From Global Phase I BEHOLD-1 Trial For Mo-Rez In Platinum-Resistant Ovarian Cancer
GSK plc reported updated phase I trial data for Mo-Rez, showing a 62% objective response rate and 12.2-month median duration of response in platinum-resistant ovarian cancer. The data will be presented at ESMO 2026, with phase III trials ongoing. Safety results were consistent with prior data, with 71% of patients experiencing grade 3 adverse events.
How this was made
The 30-second read
Why it matters
The disclosed cORR of 62% and median PFS of 11.1 months are materially better than historical outcomes in platinum‑resistant ovarian cancer, positioning GSK for a potentially valuable Phase III read‑out.
Market read
First public disclosure of robust early‑stage data for a novel oncology ADC; likely to move GSK stock and influence the broader oncology biotech sector.
What to watch
High grade 3 adverse events (71%) and ILD incidence could temper enthusiasm and affect regulatory outlook.
Background
GSK's BEHOLD program targets B7‑H4, a checkpoint protein expressed in gynecologic cancers. The BEHOLD‑1 trial is the first human study of Mo‑Rez, an ADC linking a human antibody to a topoisomerase inhibitor.
Ticker impact
GSK announced updated Phase I BEHOLD-1 trial data showing a 62% response rate and durable responses in platinum‑resistant ovarian cancer.
upward pressure as market prices in the encouraging efficacy data
First disclosure of robust response rates and durability for a novel ADC; investors typically reward such breakthroughs.
Market effects
Strengthens the oncology ADC segment and may lift peers developing B7‑H4 or similar targets.
European biotech stocks could see modest gains as the data were unveiled at a major EU conference.
Positive trial data from a large pharma can influence global biotech sentiment.
Counterpoint
Phase I data, while promising, remain early; efficacy may not translate to Phase III, so caution is warranted.
Key entities
- companyGSK plc
British‑American pharmaceutical group developing the Mo‑Rez ADC.
- drugMo‑Rez (mocertatug rezetecan)
Investigational B7‑H4‑targeted antibody‑drug conjugate.
